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Immune response to 
varicella-zoster virus before and after 
renal transplantation
Christien Rondaan, Anoek A.E. de Joode, Elisabeth Eelsing, 





Herpes zoster (HZ) risk is high in renal transplant recipients, but live-attenuated varicella-
zoster virus (VZV) vaccination is contra-indicated after transplantation. Vaccination prior 
to transplantation may be considered. It is however unclear how VZV immunity evolves 
following transplantation. Aim of the current study was to investigate VZV immunity 
before and after renal transplantation, in order to increase the understanding of VZV-
specific immune responses in this patient group. 
Methods
Immunity to VZV was determined prior to and 2-3 years after renal transplantation 
in the same 60 adult patients, and 62 matched healthy controls. VZV-specific cellular 
immunity was measured by interferon gamma (IFNγ) enzyme-linked immunospot 
(ELISpot) assay and by analyzing T-cell functionality using flowcytometry. VZV-specific IgG 
antibodies were measured using an in-house glycoprotein enzyme-linked immunosorbent 
assay (gpELISA). Medical history, including infection history, was assessed by reviewing 
medical records and for VZV infections using a questionnaire. 
Results
Numbers of IFNγ-producing cells did not change after transplantation using a paired 
analysis, but were significantly lower in transplant recipients than in controls (p = 0.028). 
Patients in whom the post-transplant period was complicated by rejection or any acute 
infection (excluding herpes zoster) had a lower number of IFNγ-producing cells than 
patients who did not. VZV-IgG levels did not significantly differ from controls, but 
a significant decrease was observed after transplantation (p < 0.0001). 
Conclusion
Cellular immunity, but not humoral immunity, against VZV is decreased in renal transplant 
recipients compared to healthy controls and is lower in patients who experienced rejection 
and acute infections other than herpes zoster in the post-transplant period. Cellular 
immunity to VZV did not significantly change following renal transplantation.
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INTRODUCTION
Herpes zoster (shingles) is characterized by neuralgia and a vesicular rash. Neuralgia can 
last for months or even years, known as postherpetic neuralgia [1,2]. The pain can have 
a major effect on a patients’ quality of life, but is often difficult to treat [3,4]. Cause of 
herpes zoster is the reactivation of a latent varicella-zoster virus (VZV) infection. After 
VZV vaccination or a primary VZV infection, known as varicella or chickenpox, the virus 
remains latently present for life in in sensory neurons of the dorsal root ganglia [1,5]. 
Being intensively treated with immunosuppressive medication, renal transplant 
recipients are known to be at increased risk of herpes zoster. Incidence in this group is 
estimated to be 28 to 37 per 1000 person years [6,7], which is 6 to 11 times higher than 
in the general population [8]. Also a high prevalence of postherpetic neuralgia of up to 
48.7% has been reported [9,10]. Disseminated disease and visceral involvement are rare 
complications that occur mainly in immunocompromised patients and may have a lethal 
outcome [11]. 
Vaccination can contribute to prevention and decreased severity of varicella and 
herpes zoster [12,13]. In contrast to the United States, routine vaccination to prevent 
varicella in children is not recommended in The Netherlands [14,15]. In The Netherlands 
almost the whole population has experienced varicella in childhood, thereby gaining VZV 
immunity through natural infection [16]. 
The currently only licensed vaccine to prevent herpes zoster in adults contains 
the same virus strain as the childhood varicella vaccine, but is at least 14 times more 
potent [17]. The zoster vaccine is thought to prevent reactivation of the latent varicella-
zoster virus by boosting pre-existing virus specific cellular immunity, and in particular 
CD4+ T cell responses, in persons latently infected with VZV [18,19]. It was shown to 
reduce the incidence of herpes zoster by 51% and of postherpetic neuralgia by 67% in 
healthy people above 60 years of age [12]. 
As the zoster vaccine contains live attenuated virus and theoretically could induce 
disseminated disease in immunosuppressed persons, even when VZV seropositive, 
the American Society of Transplantation (AST) in 2013 and the United States Advisory 
Committee on Immunization Practices (ACIP) in 2008 did not advise zoster vaccination 
after transplantation regardless of VZV serostatus [20,21]. The AST furthermore stated 
that there was insufficient data to suggest that zoster vaccination prior to transplantation 
will reduce the risk of VZV reactivation posttransplant [20]. 
Since that time zoster vaccination has been shown to be efficacious in patients with 
chronic kidney diseases above 60 years of age, with a 50% lower herpes zoster risk in 
vaccinated compared to unvaccinated patients [22]. It however remains unclear in what 
way VZV-specific immunity evolves surrounding renal transplantation and consequently, 
whether zoster vaccination prior to transplantation could be efficacious to prevent herpes 
zoster in transplant recipients. Aim of the current study was to investigate VZV immunity 
before and after renal transplantation, in order to increase the understanding of VZV-




Patients who received a renal transplant in the University Medical Center Groningen 
(UMCG) 2-3 years before inclusion and were still under supervision in this center, were 
eligible for participation. Blood was drawn at out-patient clinic visit in order to obtain 
serum and peripheral blood mononuclear cells (PBMC). Serum and PBMC of the same 
patients collected before administering induction therapy, immediately prior to the most 
recent transplantation, were retrieved from diagnostic archives from the department 
of Transplantation Immunology. Healthy control subjects were age and sex-matched 
to patients. 
Immediately before and 4 days after renal transplantation standard induction therapy 
using basiliximab (2 doses of 20 mg) was administered. Immunosuppression after 
transplantation consisted of a combination of tacrolimus or cyclosporine, in combination 
with mycophenolate mofetil and prednisolone. Prednisolone dose was gradually tapered 
and usually discontinued after three months. Choice of anti-rejection therapy depended 
on type of rejection, but generally consisted of intravenous prednisolone (3 x 1000 
mg intravenously, possibly repeated) which was followed by antithymocyte globulin or 
alemtuzumab in case of an unsatisfactory result. Amidst the study period, the protocol 
was adopted to prophylactically treat CMV-positive recipients or CMV-seronegative 
recepients receiving a graft from a CMV-positive donor with valganciclovir for the first 6 
months after transplantation.
Health insurance is mandatory in The Netherlands, covering also most specialized 
treatment. For those with low-incomes, insurance costs are compensated by 
the government.  
The study was approved by the institutional review board of the University Medical 
Centre Groningen (METc 2014/305 and 2012/375). All patients and controls gave written 
informed consent.
Clinical data, including the occurrence of varicella, herpes zoster and 
other infections
Patient characteristics and medical history (age at time of transplantation, cause of renal 
failure, multiple transplantations, renal function replacement therapy, herpes zoster, 
medication use including use of prophylactic valganciclovir after transplantation, episodes 
of rejection) were retrieved from medical records. Furthermore, medical records were 
reviewed for the occurrence of acute infections in the period between transplantation 
and study inclusion (2-3 years after transplantation). Positivity for herpes viruses, hepatitis 
viruses or BK virus were not regarded as acute infections. In The Netherlands it is custom 
to first consult a general practitioner in case of health problems, who will only refer 
in case of more serious problems. Therefore the problems that come to attention of 
a hospital specialist and, consequently, that are documented in hospital medical records, 
are generally more serious. 
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In addition to review of medical records, patients and controls were asked about their 
history and timing of varicella and herpes zoster using a questionnaire. Vaccination to 
prevent varicella in children is not part of routine immunizations, and zoster vaccination 
is not recommended for adults in The Netherlands. Therefore the whole study population 
can be regarded as non-vaccinated. 
Isolation, storage and thawing of PBMC and serum
Immediately after collection of venous blood in lithium heparin containing tubes, PBMC 
were isolated according to standard protocols and stored in liquid nitrogen until use. 
Upon thawing, cell viability was evaluated by trypan blue staining. Serum was stored 
at -20 °C until use. 
Interferon-γ (IFNγ) ELISpot assay
Interferon-γ (IFNγ) ELISpot assay was performed as previously described [23]. In short, 
per well 2 x 105 PBMC were added. Cells were stimulated using 10 µl UV-inactivated 
varicella vaccine (Provarivax; MSD, 1350 PFU/0.5 ml) or 5 µg/ml of concanavalin 
A (positive control), while a negative control consisted of PBMC in culture medium alone. 
Experiments were done in duplicate, except for the positive control. After staining and 
drying of the plates, spots were counted using an automated reader (AID EliSpot Reader; 
Autoimmun Diagnostika GmbH). Results were only accepted in case the concanavalin 
A filled well (positive control) yielded a convincingly positive result. The mean number 
of spots in the VZV-stimulated wells was corrected for the mean number of spots in 
the negative control wells. Results are referred to as the number of IFNγ spot-forming 
cells per 2 x 105 PBMC.
Flowcytometric analysis 
PBMC (1.2 x 106/tube) were stimulated using 20 µl UV-inactivated varicella vaccine, 
5 µg/ml staphylococcal enterotoxin B (SEB; Sigma-Aldrich, positive control) or left 
unstimulated (PBMC in medium alone, negative control), except for the positive control 
in the presence of 10µg/ml  anti-CD28/CD49d (Beckton Dickinson (BD)). PBMC were 
stimulated for 18 hours, of which the last 16 hours in the presence of 10 µg/ml brefeldin 
A (Sigma-Aldrich). Fluorescent T cell barcoding staining and immunostaining with 
anti-CD3, anti-CD8, anti-CD69, anti-IFNγ, anti-tumour necrosis factor alpha (TNFα) and 
anti-interleukin 2 (IL-2) was performed as described previously [24], with the addition 
of anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) (anti-CTLA-4 from BioLegend, all other antibodies from 
BD). Analyses were done using Kaluza software (Beckman Coulter). CD4+  and CD8+ 
T cell populations were gated as CD3+CD8- and CD3+CD8+, respectively. Results were 
expressed as the percentage of CD69+ cytokine/CTLA-4/PD-1 expressing CD4+ or CD8+ 
T cells within the total CD4+ or CD8+ T cell population. Furthermore, relative percentages 
of the 7 possible cytokine expression profiles within the cytokine-producing CD4+ T cell 
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population are shown. In this analysis a minimum number of 30 cytokine-producing cells 
per subject were required, in order to obtain reliable results.
Antibody levels to VZV
VZV-specific IgG antibodies were quantified using an in-house glycoprotein (gp) enzyme-
linked immunosorbent assay (ELISA), which was previously developed and validated using 
a quantitative Serion classic VZV IgG ELISA (Institut Virion/Serion) and the institution’s 
standard diagnostic test for VZV serology [23]. As antigen, VZV purified glycoproteins 
(EastCoastBio) were used. Pooled human serum with known levels of anti–glycoprotein 
VZV was used as standard. According to recommendations of Institut Virion/Serion, 
VZV-IgG levels from 50 to 100 mIU/ml were considered as borderline, while values above 
100 mIU/ml were considered positive. 
Statistical analysis
The Wilcoxon signed rank test, intended for paired analyses, was used to compare 
continuous variables before and after transplantation. Results and characteristics of 
subgroups of patients were compared using a Mann-Whitney test or Fisher’s exact test. 
Comparisons between transplant recipient (post-transplantation) and healthy control 
groups were done using a Mann-Whitney U test or Fisher’s exact test when appropriate. 
For correlations, Spearman’s rho was used.
P-values ≤0.05 (2-sided) were considered significant. Statistical analysis was performed 
using GraphPad Prism 5.03 (GraphPad Software, USA).
RESULTS
Study population
Sixty renal transplant recipients and 62 healthy control subjects were included. Their 
characteristics are summarized in Table 1. At the time of inclusion, only 1 (2%) transplant 
recipient was in need of renal replacement therapy, following rejection of the transplant 
kidney. There were no significant differences in gender and age between patient and 
control group. Moreover, no significant age/gender differences were found between 
patients who experienced rejection or infection after transplantation and those who did 
not. Patients with a history of more than 1 transplantation tended to be younger (median 
45.7 versus 55.7 years, p=0.088).
Occurrence of herpes zoster and other acute infections 
Questionnaire results, asking about history of varicella and herpes zoster, were available 
for 53 (88%) of transplant recipients. Combined with results from medical record review, 
it was determined that 13 patients (22%) had a history of herpes zoster. In four of 
these patients, timing was not known. In six, herpes zoster occurred within 2-3 years 
after most recent transplantation. One patient experienced herpes zoster only 3 weeks 
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Female gender, no. (%) 33 (53) 30 (50)
Age, median (range) years 58.4 (25.3-72.6) 55.6 (25.7-72.5)
Time since transplantation, median (range) months NA 33.7 (25.6-38.4)
Cause of renal failure, no. (%) NA
 Glomerulonephritis















 Genetic 7 (12)
 Vascular 4 (7)
 Diabetic nephropathy 5 (8)
 Congenital 2 (3)
 Urologic 3 (5)
 Chronic TIN 3 (5)
 Unknown 9 (15)
 Other 2 (3)a






 Negative/positive 0/62 0/60
History of herpes zoster, no. (%) 4 of 32 (13) 13 (22)c
Prophylactic valganciclovir, no. (%) NA 5 (8)
No. (%) of patients with post-Tx complications NA
 Rejection NA 11 (19)e
 Infection, any/bacterial/viral/fungalf NA 40/25/27/4e
No.: number, Tx: transplantation, MPGN: membranoproliferative glomerulonephritis, FSGS: focal segmental 
glomerulosclerosis, GBM: glomerular basement membrane, SLE: systemic lupus erythematosus, AAV: ANCA-
associated vasculitis, TIN: tubulointerstitial nephritis, RRT: renal replacement therapy, HD: haemodialysis, PD: 
peritoneal dialysis, VZV: varicella-zoster virus.
a One patient developed renal failure because of acute tubulus necrosis (after acute aorta rupture surgery) and 
one patient underwent nephrectomy of his one functional kidney because of transitional cell carcinoma. 
b Two patients received a transplant organ other than kidney before their most recent renal transplantation; 
one received a heart transplant and one received multiple liver transplants.
c In six patients, timing of herpes zoster was known to have occurred after most recent transplantation (within 
2-3 years before study inclusion).
d  Seven patients experienced a primary CMV infection in the post-transplantation period (within 2-3 years 
before study inclusion).
e Missing information on rejection in 2 patients and on infection (other than herpes zoster) in 1 patient. 
f More detailed information on the occurrence of infections in the 2-3 years after transplantation is provided in 
Supplementary Table S1.  
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after transplantation, and another patient immediately after rejection therapy (with 
methylprednisolone and leflunomide). No herpes zoster episodes occurred during 
prophylactic use of valganciclovir. 
Of the healthy control group, questionnaire results were available for 32 (52%) 
persons. Four (13%) stated to have experienced herpes zoster. In one subject this occurred 
only a few months prior to study participation. In the other three persons, herpes zoster 
occurred at least 15 years prior to study inclusion.
The occurrence of acute infections in the 2-3 year period between transplantation and 
study inclusion is presented in Table 1. A more detailed summary of infections occurring 
in this period is provided in Supplementary Table S1.
Numbers of IFNγ spot-forming cells in response to VZV stimulation
Number of  IFNγ spot-forming cells in response to VZV stimulation did not significantly 
change following renal transplantation. A lower number of IFNγ spot-forming cells was 
found in transplant recipients than in healthy controls (p = 0.028) (Figure 1A).
A history of more than 1 transplantation was not found to be of influence on 
numbers of IFNγ spot-forming cells to VZV, also when assessing results prior to most 
recent transplantation. The same held true for patients who were transplanted pre-
emptively versus patients treated with renal replacement therapy prior to transplantation 
(data not shown). 
Interestingly, transplant recipients in whom the post-transplantation period was 
complicated by a rejection episode, were found to have a lower number of IFNγ spot-
forming cells in response to VZV stimulation. This difference was already present prior 
to transplantation. Patients with a herpes zoster history were excluded from analysis 
(Figure 2A). 
Transplant recipients who experienced any acute infection other than herpes zoster in 
the 2-3 years post-transplantation (excluding those with a herpes zoster history) also had 
lower number of IFNγ spot-forming cells in response to VZV stimulation than those who 
did not. This difference was not yet present in the same patients prior to transplantation 
(Figure 3A). Analyzing data separately for viral or a bacterial infections yielded similar 
results (Figure S1). 
The occurrence of herpes zoster within 2-3 years before blood drawing was not of 
significant influence on number of IFNγ spot-forming cells in response to VZV stimulation, 
but number of subjects was low (n=6; Figure S2). 
Humoral immunity to VZV
All patients and controls were VZV seropositive. After transplantation VZV-IgG level was 
significantly lower than before transplantation (p<0.0001). There was no significant 
difference between healthy controls and transplant recipients (p=0.149) (Figure 1B). 
In contrast to cellular immunity results, humoral immunity to VZV was not found to 
be different in transplant recipients that experienced rejection of their transplant kidney 
immune response to VZV before and after renal transplantation 103
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(Figure 2B). Although not statistically significant, patients that experienced an acute 
infection other than herpes zoster tended to have lower antibody levels to VZV than 











































Figure 1. Numbers of interferon-γ (IFNγ) spot-forming cells in response to VZV stimulation (A) 
and levels of anti-glycoprotein (gp)VZV IgG presented on a log-scale (B) in 55/62 healthy control 
(HC) subjects and 58/59 patients before (pre) and 2-3 years after transplantation (Tx). Lines show 
the median. 
Figure 2. Numbers of interferon-γ (IFNγ) spot-forming cells in response to VZV stimulation (A) and 
levels of anti-glycoprotein (gp)VZV IgG presented on a log-scale (B) in 8 patients that experienced 
a rejection episode and 35-37 patients who did not, before (pre) and 2-3 years after transplantation 
(Tx). Patients with a history of herpes zoster were excluded from analysis. Lines show the median.
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Increased percentages of cytokine-expressing T cells prior to renal 
transplantation
Upon stimulation with VZV, high percentages of CD4+ T cells producing TNFα and IL-2 
were found in patients prior to transplantation. This phenomenon was also seen upon 
polyclonal stimulation using SEB (Figure 4A and C). 
Within CD8+ T cells, percentage of cells producing cytokines in response to VZV 
stimulation was generally lower than in the CD4+ cells, except for IL-2. For this cytokine, 
the same phenomenon was seen as in the CD4+ cells: a significantly increased cytokine 
production prior to transplantation, but similar levels in transplant recipients and control 
subjects (Figure 4B).
In response to polyclonal stimulation, again the CD8+ T cells were shown to be less 
responsive than their CD4+ counterparts. For TNFα and IL-2, expression was shown to 
decrease after transplantation, for IL-2 to levels that were significantly lower than in 
healthy controls (Figure 4D). 
Similar percentages of IFNγ-producing CD4+ and CD8+ T cells were found before and 
after transplantation, both upon stimulation with VZV and with SEB. Also, no difference 
in the percentage of T cells producing this cytokine were found between transplant 
recipients and control subjects (Figure 4A-D).


















































Figure 3. Numbers of interferon-γ (IFNγ) spot-forming cells in response to VZV stimulation (A) 
and levels of anti-glycoprotein (gp)VZV IgG presented on a log-scale (B) in 25-27 patients that 
experienced an acute infection (excluding herpes zoster) in the post-transplantation period and 19 
patients who did not, before (pre) and 2-3 years after transplantation (Tx). Patients with a history of 
herpes zoster were excluded from analysis. Lines show the median.
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No marked functional changes in VZV-specific T cells after kidney 
transplantation
The total VZV-specific CD4+ T cell population in transplant recipients consisted mainly 
of IFNγ single-positive cells. Except for a significantly lower percentage CD4+ T cells 
expressing both IFNγ and IL2 (p=0.0002) prior to transplantation, no changes before 
versus after transplantation were observed. Results were similar in transplant recipients 
and control subjects (Figure 5A).
Functionality of T cells was more diverse upon polyclonal stimulation, but again no 
marked changes following transplantation, nor differences between transplant recipients 
and controls were observed (Figure 5B). 
Mean fluorescence intensity (MFI) of programmed cell death protein 1 (PD-1) was 
higher upon stimulation with VZV than upon polyclonal stimulation, both for CD4+ and 
CD8+ T cells. No differences between transplant recipients and control subjects were 
observed (Figure 6A and B). While cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) 









































































































Figure 4. Frequencies of cytokine-producing CD4+ (A) and CD8+ (B) T cells upon stimulation 
with varicella-zoster virus (VZV), and upon stimulation with staphylococcal enterotoxin B 
(SEB, positive control) (C for CD4+ and D for CD8+ T cells) in 56 healthy control subjects (HC) 
and 59 patients before (pre) and 2-3 years after (post) receiving a renal transplant. Bars show 
the median and interquartile range. IFNγ = interferon gamma; TNFα = tumor necrosis factor alpha; 
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Figure 5. Cytokine-producing CD4+ T cells in response to stimulation with varicella-zoster virus (VZV) 
(A), and to polyclonal stimulation using staphylococcal enterotoxin B (SEB) (B) divided according 
to expression of interferon gamma (IFNγ), tumour necrosis factor alpha (TNFα) and interleukin-2 
(IL2), and co-expression of combinations of these cytokines in 56 healthy control (HC) subjects 
and 59 patients before (pre) and 2-3 years after (post) receiving a renal transplant (Tx). Presented 
percentages are relative percentages of the total population of cytokine-producing CD4+ T cells in 
response to stimulation with VZV or SEB. Bars show the median and interquartile range.
MFI on CD4+ T cells was significantly lower in patients prior to transplantation, it was 
significantly increased in these patients on CD8+ T cells. No marked differences between 
transplant recipients and controls were seen (Figure 6C and D).  
Figures representing percentages of T cells expressing PD-1 and CTLA-4 are available 
online (Figure S3).
Correlations
A weak correlation between age and cellular immunity to VZV (number of IFNγ spot-
forming cells) (ρ = -0.389, p = 0.002) was present in transplant recipients. No significant 
correlations were found between age and humoral immunity to VZV, or between humoral 
and cellular immunity to VZV (data not shown).
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DISCUSSION
In this study, VZV-specific immunity was evaluated in the same 60 patients before and 
after renal transplantation. Cellular immunity to VZV, as assessed by an IFNγ ELISpot assay, 
did not significantly change after transplantation. The number of IFNγ spot-forming cells 
in response to VZV stimulation was however shown to be significantly lower in transplant 
recipients than in control subjects. VZV-specific humoral immunity in transplant recipients 
did not significantly differ from controls, but a significant decrease was observed 
after transplantation. 
Cellular immunity to VZV is considered to be essential in the immune response to VZV 
and prevention of herpes zoster. Number and functionality of VZV-specific CD4+ T cells 
have been shown to be impaired in immunocompromised patient groups at increased 
risk of herpes zoster [25,26]. Responding cells in the IFNγ ELISpot assay consist mostly 
out of CD4+ T cells. This assay, which tests functionality of VZV-specific cells, is generally 
considered to be a reliable method for the assessment of VZV-specific cellular immunity 
[27]. Previously, decreased numbers of IFNγ spot-forming cells upon VZV stimulation have 
been demonstrated in the elderly and different immunocompromised patient groups at 
increased risk of herpes zoster [23,28-31]. Our finding of a lower number of IFNγ spot-
forming cells upon VZV stimulation in transplant recipients compared to controls is in line 























































































Figure 6. Mean fluorescence intensity (MFI) of programmed cell death protein 1 (PD-1) on CD4+ (A) 
and CD8+ (B) T cells, and of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on CD4+ (C) and 
CD8+ (D) T cells upon stimulation with varicella-zoster virus (VZV) and staphylococcal enterotoxin B 
(SEB, positive control) in 28 healthy control subjects (HC) and 59 patients before (pre) and 2-3 years 
after (post) receiving a renal transplant. Bars show the median and interquartile range. 
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with the reported increased herpes zoster incidence in this group [6,7,32]. Although they 
reported a lower percentage of VZV-specific CD8+ effector memory cells in patients, Van 
Besouw et al. did not find a difference in percentage of subsets of VZV-reactive CD4+ 
T cells between 11 renal transplant recipients and 21 controls, using intracellular IFNγ 
flowcytometry [33]. Flowcytometry has been shown to be less likely than ELISPOT to 
detect low-level responses [27].    
Interestingly, in response to VZV stimulation a lower number of IFNγ spot-forming cells 
was present in transplant recipients in whom post-transplant period was complicated by 
rejection or acute infections other than herpes zoster. Anti-rejection therapy was previously 
identified to be a significant risk factor for the development of herpes zoster in renal 
transplant recipients [32], but as the difference was also present before transplantation 
this could indicate that a suboptimal immune system is already present in these patients 
prior to transplantation. Age is a well-known risk factor for herpes zoster, and has been 
shown to be associated with impaired cellular immunity to VZV [34]. This is in line with 
our finding of an inverse correlation between number of IFNγ spot-forming cells and age 
of transplant recipients. 
Next to evaluating cellular immunity to VZV using an IFNγ ELISpot assay, we evaluated 
cytokine production of CD4+ and CD8+ T cells in response to stimulation with VZV. 
Cytokine production was shown to be high prior to transplantation, but did not differ 
between transplant recipients and control subjects. As this phenomenon was also seen 
upon polyclonal stimulation, it was not VZV-specific. Hypercytokinaemia could be an 
explanation of our findings, which is known to occur in chronic kidney disease patients, 
and is thought to be associated with uraemia [35,36]. 
Schub et al. reported a significantly lower percentage of CD4+ T cells concomitantly 
producing 3 cytokines in response to VZV stimulation in transplant recipients compared 
to controls, while percentage of cells only producing IFNγ was increased. They suggested 
that multifunctionality of  specific T cells is correlated with sufficient pathogen control 
[25]. In the current study we did not find marked differences in VZV-specific CD4+ T 
cell functionality between transplant recipients and controls. In both groups, median 
share of cells producing only IFNγ comprised approximately half of the total VZV-specific 
CD4+ T cell population. The reason for the different findings is not clear, but may in part 
be caused by differences in patient population between countries with (Germany) and 
without (The Netherlands) routine childhood varicella vaccination. Furthermore, there 
were differences between the studies in stimulation time of T cells and using cryopreserved 
PBMC versus whole blood [25]. 
Upregulation of inhibitory receptors such as PD-1 and CTLA-4 has been identified as an 
important feature of exhausted T cells. Exhausted T cells, resulting from a persistent (viral) 
infection, are less able to exert their effector functions [37,38]. As we found the expression 
of inhibitory receptors PD-1 and CTLA-4 to be similar in transplant recipients and controls, 
we could also not confirm the finding of an increased PD-1 expression on CD4+ T cells in 
transplant recipients upon polyclonal stimulation, as reported by Schub et al.[25]. Mean 
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fluorescence intensity of PD-1 was higher upon VZV stimulation than upon polyclonal 
stimulation. This may be explained by the physiologic role of PD-1 in the regulation of 
immune responses towards a specific antigen [37,39]. 
Clinical VZV vaccination studies in solid organ transplant recipients or patients awaiting 
solid organ transplantation to date have mainly focused on prevention of varicella in 
VZV seronegative patients, mostly children. Vaccination generally appears to be safe 
and immunogenic in these patients [40-43], although immunogenicity may be reduced 
compared to healthy control subjects [44]. In a recent study by Kho et al., adult renal 
transplant candidates with undetectable VZV-IgG levels, were vaccinated using a live 
attenuated varicella vaccine. Cellular immunity to VZV was evaluated in 11 patients before 
vaccination and after transplantation (median 7.2 months after transplantation). While 
total number of leukocytes decreased, percentage of VZV-specific CD4+ memory T cells 
was shown to significantly increase, indicating that pre-transplant VZV vaccination may be 
useful. As cellular immunity between vaccination and transplantation was not evaluated, 
effect of the transplant procedure itself on VZV immunity however remained unclear [45]. 
The effect on post-transplant herpes zoster incidence of vaccinating seropositive persons 
before solid organ transplantation to date has not been sufficiently studied.  
This study has several limitations. Firstly, information regarding herpes zoster and 
other infections could have been missing from medical records as these do not necessarily 
come to attention of a hospital specialist. Moreover, questionnaire results on herpes 
zoster occurrence did not seem completely reliable, with at least two patients not 
mentioning a herpes zoster episode that was noted in medical records. As many patients 
and controls did not reliable recall occurrence and timing of varicella, it could not be 
determined whether age at first encounter with VZV was of influence on VZV immunity. 
Furthermore, differences in VZV-immunity between diagnostic subgroups could not be 
reliably evaluated because of the limited number of patients in the different subgroups. 
Lastly, T cell tests are not standardized and results differ greatly between publications. 
Therefore comparing different studies is difficult. 
In conclusion, no marked changes in cellular immunity to VZV following renal 
transplantation were observed. However, transplant recipients were shown to have 
a lower cellular immunity to VZV than matched control subjects, corresponding with 
a high herpes zoster risk in these patients. Transplant recipients that experienced rejection 
or infection in the post-transplant period seemed to be at even higher risk. In contrast to 
cellular immunity, humoral immunity to VZV was shown to decrease significantly following 
transplantation, but resulting levels were not different from levels in healthy control 
subjects. Future research should focus on the post-transplant effect on herpes zoster 
incidence of vaccinating VZV seropositive patients before solid organ transplantation. 
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SUPPLEMENTARY DATA
Supplementary Table 1. Infections in the 2-3 years post-transplant period 
No. (%)
Viral
  Herpes zoster
  Gastroenteritis (mostly norovirus)
  Primary CMV infection
  Primary EBV infection/EBV reactivation
  Rhinovirus 
  Influenza










  Urinary tract infection
  Gastroenteritis
  Skin infection requiring antibiotic treatment
  Pneumonia










No.: number, CMV: cytomegalovirus, EBV: Epstein-Barr virus
a Total of self-reported herpes zoster infections (using questionnaire) and herpes zoster infections documented 
in medical records was 13. Three cases occurred before the most recent transplantation. In four cases, timing 
was unknown.
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Supplementary figure 1. Numbers of interferon gamma (IFNγ) spot-forming cells in response 
to VZV stimulation (A) and levels of anti-glycoprotein (gp)VZV IgG presented on a log-scale (B) 
in 13/14 patients who experienced an acute viral infection, 18/19 patients who experienced an 
acute bacterial infection and 19 patients without documented infections in the 2-3 years after 
transplantation. Results before (pre) and after (post) transplantation (Tx) are shown. Patients with 
a history of herpes zoster were excluded from analysis. Lines show the median.
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Supplementary figure 2. Numbers of interferon gamma (IFNγ) spot-forming cells in response 
to VZV stimulation (A) and levels of anti-glycoprotein (gp)VZV IgG presented on a log-scale (B) in 
6 patients who experienced herpes zoster (HZ) in the 2-3 years after transplantation compared to 
45/47 patients without any mentioning of herpes zoster (no HZ) in records/questionnaire. Lines 
show the median. 
Supplementary figure 3. Percentage of cells expressing programmed cell death protein 1 (PD-1) of 
CD4+ (A) and CD8+ (B) T cells, and percentage of cells expressing cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4) of CD4+ (C) and CD8+ (D) T cells upon stimulation with varicella-zoster virus 
(VZV) and staphylococcal enterotoxin B (SEB, positive control) in 28 healthy control subjects (HC) 
and 59 patients before (pre) and 2-3 years after (post) receiving a renal transplant. Bars show 
the median and interquartile range.
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